Ciforadenant (CPI-444)
Renal Cell Carcinoma
Phase 1b/2Active (via partner Corvus)
Key Facts
Indication
Renal Cell Carcinoma
Phase
Phase 1b/2
Status
Active (via partner Corvus)
Company
About angel-pharmaceuticals
A Chinese biotech developing first-in-class and best-in-class oncology/autoimmune drugs through global partnerships and internal R&D.
View full company profileTherapeutic Areas
Other Renal Cell Carcinoma Drugs
| Drug | Company | Phase |
|---|---|---|
| LW-02 Immunopheresis | Immunicom | Phase 2 |
| CB-839 (Telaglenastat) | Calithera Biosciences | Phase 2 |
| XS008 (axitinib) | Xspray Pharma | Preclinical/Development |
| CDK7 allosteric inhibitor | Acellera | Pre-clinical |
| Precision Oncology - RCC | ReviveMed | Discovery |
| Lenvatinib (LENVIMA) | eisai | Regulatory Review |
| Cabozantinib | exelixis | Phase 3 |
| Zanzalintinib (XL092) | exelixis | Phase 3 |
| Casdatifan (AB521) | arcus-biosciences | Phase 3 |
| XmAb®819 | xencor | Phase 1 |
| MINC‑sunitinib | suntec-medical | Preclinical |